NEOGEN CORP

NEOGNasdaq· In Vitro & In Vivo Diagnostic Substances

Price History

Revenue

$894.7M

▼ 3.2% YoY

Net Income

-$1.1B

▼ 11491.6% YoY

EPS

$-5.03

▼ 12475.0% YoY

Cash

$129.0M

▼ 24.4% YoY

FY 2025 · As of 2025-05-31

Pro

10-K Year-over-Year Diff

AI-powered analysis of what changed between the last two annual reports — new risks, removed language, strategy shifts.